Jump to navigation Jump to search
|(what is this?)|
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009[update], it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.